| Ident. | Authors (with country if any) | Title |
|---|
| 000093 (2021) |
Derek Shyr [États-Unis] ; Yu Shyr [États-Unis] | The design and analysis of non-randomized studies: a case study of off-label use of hydroxychloroquine in the COVID-19 pandemic. |
| 000160 (2021) |
Saeidreza Jamalimoghadamsiahkali [Iran] ; Besharat Zarezade [Iran] ; Sogol Koolaji [Iran] ; Seyedahmad Seyedalinaghi [Iran] ; Abolfazl Zendehdel [Iran] ; Mohammad Tabarestani [Iran] ; Ehsan Sekhavati Moghadam [Iran] ; Ladan Abbasian [Iran] ; Seyed Ali Dehghan Manshadi [Iran] ; Mohamadreza Salehi [Iran] ; Malihe Hasannezhad [Iran] ; Sara Ghaderkhani [Iran] ; Mohsen Meidani [Iran] ; Faeze Salahshour [Iran] ; Fatemeh Jafari [Iran] ; Navid Manafi [Canada] ; Fereshteh Ghiasvand [Iran] | Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial. |
| 000195 (2021) |
Philippe Gautret [France] ; Van Thuan Hoang [Viêt Nam] ; Jean-Christophe Lagier [France] ; Didier Raoult [France] | Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial. |
| 000218 (2021) |
Marcelo Rodrigues Dos Santos [Brésil] | Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial. |
| 000230 (2021) |
Faryal Khamis [Oman] ; Hanan Al Naabi [Oman] ; Adil Al Lawati [Oman] ; Zaiyana Ambusaidi [Oman] ; Mariam Al Sharji [Oman] ; Umkulthum Al Barwani [Oman] ; Nenad Pandak [Oman] ; Zakariya Al Balushi [Oman] ; Maher Al Bahrani [Oman] ; Issa Al Salmi [Oman] ; Ibrahim Al-Zakwani [Oman] | Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. |
| 000267 (2021) |
Raymond Chee Seong Seet [Singapour] ; Amy May Lin Quek [Singapour] ; Delicia Shu Qin Ooi [Singapour] ; Sharmila Sengupta [Singapour] ; Satish Ramapatna Lakshminarasappa [Singapour] ; Chieh Yang Koo [Singapour] ; Jimmy Bok Yan So [Singapour] ; Boon Cher Goh [Singapour] ; Kwok Seng Loh [Singapour] ; Dale Fisher [Singapour] ; Hock Luen Teoh [Singapour] ; Jie Sun [Singapour] ; Alex R. Cook [Singapour] ; Paul Anantharajah Tambyah [Singapour] ; Mikael Hartman [Singapour] | Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. |
| 000295 (2021) |
Zheng Zequn [République populaire de Chine] ; Wu Yujia [République populaire de Chine] ; Qian Dingding [République populaire de Chine] ; Lian Jiangfang [République populaire de Chine] | Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel. |
| 000296 (2021) |
Victoria Birlutiu ; Rares Mircea Birlutiu ; Liana Chicea [Roumanie] | Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience. |
| 000356 (2021) |
Mohamed O. Saad [Qatar] | Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial". |
| 000448 (2021) |
Philippe Gautret [France] ; Jean-Christophe Lagier [France] ; Stéphane Honoré [France] ; Van Thuan Hoang [Viêt Nam] ; Philippe Colson [France] ; Didier Raoult [France] | Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited. |
| 000479 (2021) |
Carlos Gustavo Wambier [États-Unis] | Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial". |
| 000542 (2021) |
Philippe Gautret [France] ; Van Thuan Hoang [Viêt Nam] ; Jean-Christophe Lagier [France] ; Didier Raoult [France] | Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes. |
| 000546 (2021) |
Luis Gabriel Parra-Lara [Colombie] ; Juan José Martinez-Arboleda [Colombie] ; Daniel Francisco Isaza-Pierotti [États-Unis] ; Fernando Rosso [Colombie] | Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial. |
| 000565 (2021) |
Iwein Gyselinck [Belgique] ; Laurens Liesenborghs [Belgique] ; Ewout Landeloos [Belgique] ; Ann Belmans [Belgique] ; Geert Verbeke [Belgique] ; Peter Verhamme [Belgique] ; Robin Vos [Belgique] ; W. Janssens [Belgique] | Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial. |
| 000611 (2021) |
Mary Kelly [Irlande (pays)] ; R Isìn O'Connor [Irlande (pays)] ; Liam Townsend [Irlande (pays)] ; Miriam Coghlan [Irlande (pays)] ; Eileen Relihan [Irlande (pays)] ; Miriam Moriarty [Irlande (pays)] ; Bernard Carr [Irlande (pays)] ; Gail Melanophy [Irlande (pays)] ; Caitriona Doyle [Irlande (pays)] ; Ciaran Bannan [Irlande (pays)] ; Ruth O'Riordan [Irlande (pays)] ; Concepta Merry [Irlande (pays)] ; Susie Clarke [Irlande (pays)] ; Colm Bergin [Irlande (pays)] | Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin. |
| 000726 (2021) |
Annie Delaunois [Belgique] ; Matthew Abernathy [États-Unis] ; Warren D. Anderson [États-Unis] ; Kylie A. Beattie [Royaume-Uni] ; Khuram W. Chaudhary [États-Unis] ; Julie Coulot [Suisse] ; Vitalina Gryshkova [Belgique] ; Simon Hebeisen [Suisse] ; Mark Holbrook [Royaume-Uni] ; James Kramer [États-Unis] ; Yuri Kuryshev [États-Unis] ; Derek Leishman [États-Unis] ; Isabel Lushbough [Belgique] ; Elisa Passini [Royaume-Uni] ; Will S. Redfern [Royaume-Uni] ; Blanca Rodriguez [Royaume-Uni] ; Eric I. Rossman [États-Unis] ; Cristian Trovato [Royaume-Uni] ; Caiyun Wu [États-Unis] ; Jean-Pierre Valentin [Belgique] | Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off-label in the first wave of COVID-19. |
| 000741 (2021) |
Álvaro Réa-Neto [Brésil] ; Rafaella Stradiotto Bernardelli [Brésil] ; Bruna Martins Dzivielevski Câmara [Brésil] ; Fernanda Baeumle Reese [Brésil] ; Marcos Vinicius Oliveira Queiroga [Brésil] ; Mirella Cristine Oliveira [Brésil] | An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients. |
| 000885 (2020) |
Alexandre Gérard [France] ; Serena Romani [France] ; Audrey Fresse [France] ; Delphine Viard [France] ; Nadège Parassol [France] ; Aurélie Granvuillemin [France] ; Laurent Chouchana [France] ; Fanny Rocher [France] ; Milou-Daniel Drici [France] | "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. |
| 000C42 (2020) |
Ehsan Sekhavati [Iran] ; Fatemeh Jafari [Iran] ; Seyedahmad Seyedalinaghi [Iran] ; Saeidreza Jamalimoghadamsiahkali [Iran] ; Sara Sadr [Iran] ; Mohammad Tabarestani [Iran] ; Mohammad Pirhayati [Iran] ; Abolfazl Zendehdel [Iran] ; Navid Manafi [Iran] ; Mahboubeh Hajiabdolbaghi [Iran] ; Zahra Ahmadinejad [Iran] ; Hamid Emadi Kouchak [Iran] ; Sirous Jafari [Iran] ; Hosein Khalili [Iran] ; Mohamadreza Salehi [Iran] ; Arash Seifi [Iran] ; Fereshteh Shahmari Golestan [Iran] ; Fereshteh Ghiasvand [Iran] | Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial. |
| 000D01 (2020) |
Frits R. Rosendaal [Pays-Bas] | Review of: "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949. |
| 000F12 (2020) |
J Simon Bell ; John A. Bell ; Darren J. Creek | Off-label prescribing in the midst of a pandemic: The case of hydroxychloroquine. |
